Cord Blood Transplant Success Rates: What the Data Actually Says
Cord blood transplant outcomes have improved substantially since the first transplant in 1988. The headline numbers depend heavily on the disease being treated, the patient's age, and how well the donor unit matches.
Overall survival benchmarks
For pediatric patients with acute leukemia, published studies and CIBMTR (Center for International Blood and Marrow Transplant Research) data report 3-year overall survival in the range of roughly 60–70% after cord blood transplant, comparable to matched unrelated bone marrow transplant for similar patients. Adult outcomes are lower, generally 40–55% at 3 years, largely because adults need higher cell doses.
Engraftment: the first hurdle
Engraftment is when transplanted stem cells start producing new blood cells. Cord blood engrafts more slowly than bone marrow — typically 22–28 days for neutrophils versus 16–20 — and roughly 80–90% of single-unit cord blood transplants achieve engraftment. Double cord blood transplants and ex vivo expansion techniques have improved this for adults.
Why matching matters less for cord blood
Cord blood stem cells are immunologically 'naive', so they tolerate HLA mismatches better than bone marrow. A 4-of-6 HLA match is often acceptable for cord blood, while bone marrow typically needs 8-of-8 or 10-of-10. This is the main reason cord blood expanded transplant access for patients from diverse ethnic backgrounds, who historically struggled to find matched bone marrow donors.
What 'success' usually measures
- Overall survival (OS) at 1, 3, or 5 years
- Disease-free survival (DFS)
- Engraftment rate and time to engraftment
- Treatment-related mortality (TRM) in the first 100 days
- Incidence of graft-versus-host disease (GVHD)